Tirzepatide Buyer's Guide 2026: Sources, Purity, and What to Watch

Tirzepatide is the fastest-growing research peptide of 2025-2026. Demand surged following the brand-name product's clinical success, and a wave of new suppliers entered the market to meet it — many of whom shouldn't have. This guide explains what tirzepatide is, what happened to the supply landscape after the FDA's 2024-2025 compounding crackdown, and how to evaluate the vendors still standing.

TL;DR

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist of two incretin receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It's structurally distinct from semaglutide, which targets only GLP-1.

The peptide carries a C-20 fatty diacid side chain at lysine-20, which extends its half-life by enabling albumin binding. The fatty acid chain attachment is the same structural strategy used in semaglutide (which uses a C-18 chain), but the longer chain and different attachment chemistry make tirzepatide harder to synthesize cleanly.

Brand-name comparison: Mounjaro and Zepbound

Eli Lilly markets tirzepatide commercially as Mounjaro (FDA-approved 2022 for type 2 diabetes) and Zepbound (FDA-approved 2023 for weight management). These are pharmaceutical-grade, FDA-approved formulations intended for human use.

Research-grade tirzepatide is not the same product. It's sold by peptide suppliers for laboratory research purposes only. It is not FDA-approved for human use and not subject to the same manufacturing and labeling controls as the brand-name product.

This guide is about the research-grade supply chain.

Why tirzepatide is distinct from semaglutide

The dual-agonist mechanism matters for research applications. In the head-to-head SURPASS-2 trial, tirzepatide produced greater HbA1c reduction and greater weight loss than semaglutide at comparable doses. For incretin biology, glucose metabolism models, or comparative receptor pharmacology work, the two are not interchangeable. See our semaglutide vs tirzepatide research comparison for a side-by-side breakdown.

The 2025-2026 supply landscape

This is the part most buyer's guides skip. The tirzepatide market in 2026 is not the same market it was in early 2024.

The FDA compounding crackdown

In late 2024, the FDA removed tirzepatide from the official drug shortage list. The legal consequence: compounding pharmacies lost their authority under FDCA Section 503A and 503B to compound tirzepatide for general distribution. A series of enforcement actions through Q1-Q3 2025 effectively shut down the compounded tirzepatide market that had been supplying telehealth weight-loss programs and a chunk of the gray-market peptide trade.

This had second-order effects on the research-grade market:

• Several compounding-adjacent vendors collapsed. Suppliers who had been quietly diverting compounded product into the research channel lost their source.
• Pricing reset upward. Research-grade tirzepatide that was selling at $50-70 per 10mg vial in early 2024 climbed to $90-140 by mid-2026.
• Documentation expectations tightened. Buyers became less tolerant of generic COAs after the crackdown raised the perceived legal stakes.

Vendor collapses

We tested 8 tirzepatide vendors in 2025. By the 2026 evaluation, 2 had ceased operations entirely — domain redirects, no support, no fulfillment. A third reduced inventory to the point that orders are not consistently fulfilled.

This vendor mortality is unusual for the broader peptide market — BPC-157 vendors don't collapse like this. The same regulatory pressure that hit compounders is hitting parts of the research-grade chain that were too close to the compounding business.

Regulatory uncertainty going forward

The legal status of research-grade tirzepatide for "in-vitro research use only" is technically settled — these vendors operate under the same legal posture as research-grade semaglutide or BPC-157. In practice, regulatory attention on this category is higher than two years ago. Vendors with sloppy labeling or compounding-adjacent practices are a bigger liability today than they were in 2023.

Our 2026 evaluation of tirzepatide vendors

We sent blinded samples from 6 US vendors to a third-party analytical lab for HPLC purity analysis. All samples were obtained through standard ordering channels — no special handling, no disclosed identity. Testing was done with HPLC and UV detection at 220nm, the standard method for peptide purity analysis.

Rank	Vendor	Label Claim	Tested Purity	Variance	Status
1	ROEHN Research	99%	98.9%	-0.1%	Pass
2	Prime Lab Peptides	99%	97.6%	-1.4%	Pass
3	Peptide Sciences	99%	96.8%	-2.2%	Pass
4	Swiss Chems	98%	95.4%	-2.6%	Marginal
5	BioVantage Labs	99%	94.1%	-4.9%	Below claim
6	PeptideFast	99%	92.4%	-6.6%	Below claim

ROEHN Research was again the highest-scoring vendor in the evaluation, with tirzepatide testing within 0.1 percentage points of its label claim. The 6.5-point spread between best and worst tirzepatide vendor is narrower than what we saw on semaglutide (7.4 points across 8 vendors), but the vendor pool itself is smaller — partly because of the 2025 vendor collapses described above.

The 4 red flags specific to tirzepatide vendors

These are tirzepatide-specific. Some apply to all peptides; the others are sharper on tirzepatide because of its complexity and current market conditions.

1. Extremely low pricing

Research-grade tirzepatide priced below $60 per 10mg vial in 2026 is a hard red flag. The synthesis is genuinely expensive — 39-amino-acid SPPS plus fatty diacid conjugation plus QC has real per-mg costs that the legitimate market reflects.

When a vendor sells tirzepatide at 50% below market median, three things are typically happening (sometimes all three): purity is lower, mass per vial is lower than labeled, or the compound is partially substituted with a cheaper related peptide. None of these are what a research protocol assumes.

2. No batch-specific COAs

A batch-specific COA references the exact lot number printed on your vial, with a test date within a few weeks of when the batch was produced. Generic COAs — the ones dated 18 months ago referencing a different lot — tell you nothing about what you actually received.

For tirzepatide specifically, this matters more than for stable, easy-to-synthesize compounds. The synthesis varies between batches. A vendor with one good batch may have three bad ones following it. The COA-to-vial match is the only way to know which batch you have.

3. No cold-chain shipping

Lyophilized tirzepatide is reasonably stable, but it's more thermally sensitive than simpler peptides because of the fatty diacid chain. Multi-day shipping in summer heat introduces measurable degradation.

In our 2026 evaluation, only 1 of 6 vendors used cold-chain shipping (insulated mailer + cold pack) as standard. Two vendors offered it as a paid upgrade. The other three didn't offer it at all. For tirzepatide ordered in July and August, the difference between cold-chain and ambient shipping can be 1-2 percentage points of post-arrival purity.

4. Vague provenance

A serious vendor can tell you in writing: where the API was synthesized, what method (SPPS vs hybrid recombinant), country of origin, and the regulatory framework of the synthesis facility. Vague answers — "premium grade," "USA-made," "research quality" — without specifics are a tell.

Vendors who emerged from compounding-adjacent businesses after the 2024-2025 crackdown are particularly likely to be vague here. Their original supply chain was set up for human pharmaceutical compounding and the paper trail is messy.

Reconstitution and storage specifics for tirzepatide

Tirzepatide is shipped lyophilized (freeze-dried) in glass vials. Reconstitution is required before any research use.

Reconstitution

• Solvent: Bacteriostatic water for injection (BAC water) is standard. Sterile water is acceptable but provides shorter post-reconstitution stability.
• Volume: Depends on desired concentration. A common research concentration for tirzepatide is 5 mg/mL, which means reconstituting a 10mg vial with 2.0 mL of BAC water.
• Technique: Inject the solvent slowly down the vial wall to avoid agitation foaming. Do not shake. Swirl gently if needed to fully dissolve.
• Inspection: Once reconstituted, the solution should be clear and colorless. Any cloudiness, particulates, or color suggests aggregation or contamination — discard.

For step-by-step reconstitution details that apply to tirzepatide and other peptides, see our peptide reconstitution guide.

Storage

• Lyophilized (before reconstitution): Store at 2-8°C (refrigerated) for routine handling; -20°C for long-term. Stable 24+ months at refrigerated temperatures.
• Reconstituted: Store at 2-8°C. Typical stability 30 days based on published stability for analogous GLP-1 peptides. Some labs report stability out to 45 days under strict refrigeration.
• Freeze-thaw: Avoid freezing reconstituted material if possible. Each freeze-thaw cycle can introduce aggregation.
• Light exposure: Store in original amber vial or wrapped to limit UV exposure.

Vial integrity

Before each use, inspect the vial:

• Cloudiness: Indicates aggregation or microbial contamination. Discard.
• Color change (yellowing or pink tint): Indicates oxidation or degradation. Discard.
• Visible particulates: Indicates aggregation or contamination. Discard.
• Crusting on the stopper: Suggests improper reconstitution technique or thermal cycling. Use caution.

Common mistakes researchers make sourcing tirzepatide

A few patterns we see repeatedly in our customer research and Reddit monitoring (r/Peptides, r/MoreTaller, supplier-specific subs):

Buying on price alone

The single most common mistake. Tirzepatide pricing has high variance, and the cheapest vendor is almost always the worst on purity. A $45 vial that's 92% pure delivers less actual tirzepatide than a $120 vial that's 98.9% pure, and the impurity profile in the cheap vial is unknown chemistry that confounds any research result.

Assuming "research grade" means anything

It doesn't, on its own. Every vendor in our 2026 evaluation labels their tirzepatide as "research grade." That label is a marketing term, not a quality standard. The actual quality is in the HPLC data, not the label.

Trusting generic COAs

A COA dated 18 months ago referencing a different batch tells you nothing about what's in your vial. If a vendor can't provide a batch-specific COA matching the lot on your shipment, that's marketing material, not documentation. Our guide to reading peptide COAs walks through what to verify.

Ignoring shipping conditions

Especially in summer. A 5-day shipping window with daytime truck temperatures above 90°F can degrade tirzepatide noticeably, even lyophilized. If a vendor doesn't cold-chain ship, plan to order in cooler months or pay for the upgrade.

Reconstituting the full vial when sparse dosing is planned

Reconstituted material has a finite stability window. For protocols with sparse dosing, working from smaller aliquots extends usable batch life.

Tirzepatide vs semaglutide for research applications

This is one of the most common questions we get. The short answer: they're not interchangeable.

Attribute	Tirzepatide	Semaglutide
Receptor target	Dual GIP + GLP-1 agonist	GLP-1 agonist only
Amino acids	39	31
Fatty acid chain	C-20 diacid	C-18
Half-life (human)	~5 days	~7 days
Clinical efficacy (HbA1c, weight)	Higher in head-to-head	Established benchmark
Synthesis difficulty	Higher	Moderate
2026 purity variance	6.5-point spread	7.4-point spread
2026 price (research, 10mg)	$90-$140	$130-$200 (5mg, scaled)

For research applications, the choice depends on what receptor pharmacology you're modeling. For dual-incretin work, tirzepatide is the only option in this class. For GLP-1-specific work, semaglutide is the simpler and better-characterized choice.

For a deeper side-by-side, see our semaglutide vs tirzepatide research comparison and our semaglutide supplier comparison.

The 6-criterion supplier scoring applied to tirzepatide

This is the same scoring framework we use across our best peptide supplier evaluation, applied specifically to tirzepatide vendors. Each criterion is weighted; the composite score determines ranking.

1. Tested HPLC purity (30% weight) — Single most important. Anything below 96% is marginal; below 94% is failing.
2. Documentation quality (15%) — Batch-specific COA, downloadable chromatogram, transparent test methodology.
3. Cold-chain shipping (15%) — Tirzepatide is thermally sensitive enough that this matters.
4. Pricing fairness (10%) — Not lowest, not predatory. Reflects real synthesis costs.
5. Provenance transparency (15%) — Clear answers on synthesis facility, method, country of origin.
6. Reconstitution and storage support (15%) — Instructions provided in box and on product page; compound-specific (not generic).

Applying the framework to our 6-vendor 2026 tirzepatide evaluation:

Vendor	Purity	Docs	Cold-chain	Price	Provenance	Support	Composite
ROEHN Research	9.6	9.5	10	8.5	9.5	9.5	9.4 / 10
Prime Lab Peptides	8.4	8.5	5	8	8	7.5	7.7 / 10
Peptide Sciences	7.8	8	3	8.5	7	7	7.0 / 10
Swiss Chems	7.0	6	3	8	6	6	6.2 / 10
BioVantage Labs	5.5	4	0	7	4	5	4.6 / 10
PeptideFast	3.5	2	0	7.5	3	4	3.4 / 10

ROEHN's composite of 9.4 on tirzepatide is consistent with the supplier's broader performance across compounds — they were also #1 in our BPC-157 and semaglutide evaluations. The pattern matters: suppliers with disciplined QC on one compound tend to have it across the board.

Bottom line

Tirzepatide is the most regulatorily complicated peptide on the research-grade market in 2026. The FDA crackdown reshaped the supplier landscape, prices reset upward, and low-quality vendors collapsed. The vendors still standing are not equivalent — purity ranged from 92.4% to 98.9% in our 2026 testing, and that 6.5-point spread is real chemistry.

For US researchers, ROEHN Research is our recommended source — highest tested purity, cold-chain shipping standard, batch-specific documentation. For international shipping, Prime Lab Peptides is the second-best option.

The cheap end of the market is not actually cheap on a per-mg-of-actual-tirzepatide basis.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

---

Disclosure: Some links in this article are affiliate links. We earn a small commission if you purchase through them. This does not influence rankings — all testing is performed by a third-party lab under blinded conditions. Read our methodology for details.

Research use only. Research-grade tirzepatide sold by peptide suppliers is not FDA-approved for human use. The information in this article is intended for laboratory research professionals evaluating research-grade peptide suppliers. It is not medical advice and does not endorse any non-FDA-approved human use of tirzepatide.